Global Fiducial Markers Market Expectations & Growth Trends Highlighted until 2028

The tier 1 players in the fiducial markers market hold around 60-70% revenue share. The growth of tier 1 players can be accredited to their robust product portfolios and differentiated strategies in tune with changing nature of the market and evolving end-user specifications.

With persistent focus on effective devices, offering accuracy and precision in the healthcare space, the tier 1 companies in the fiducial markers market are focused on novel product developments taking usability to the next level. Continual emphasis on product developments and innovations enables these players to retain their brand equity and solidify their sustenance in the global market space.

Fiducial Markers Surge in Popularity as a Standard Tool for Image-Guided Radiotherapy (IGRT)

Fiducial markers are gaining immense traction as a standard tool for image-guided radiotherapy (IGRT), owing to enhanced precision in terms of results. Acting as reliable surrogates for effectively imaging the anatomic structures, fiducial markers are evolving as an imperative for modern radiotherapy that rapidly resorting to conformal delivery techniques.

With conventional procedures overshadowing imaging accuracy, fiducial markers evolved as a new breakthrough that enabled doctors to have a target area within the field of view and ensure accurate results. In case of prostate cancer cases with floating nature of tumors, fiducial markers are being increasingly adopted for effective diagnosis with optimal accuracy and precision.

Rising Inclination toward Minimally Invasive Procedures to Hamper Adoption

The preference for minimally invasive procedures is on a continual rise by virtue of lessened pain and minimum risk of infection associated. As per a revelation by the National Health Service (NHS), cancer patients requiring radiotherapy or brachytherapy are highly oriented toward minimally invasive procedures to experience a pain-free diagnosis.

Interventions making use of fiducial markers are invasive in nature and entails a surgery for appropriate positioning of the marker, which is a key factor that might hinder the adoption rate. The increasing embracement of minimally invasive procedures is taking its toll on the adoption rate of fiducial markers, which involves an implantation procedure for target localizing.

Rise in Demand for MRI Non-Magnetic Fiducial Markers – A Prominent Trend

Magnetic resonance imaging technique remains a popular technique used in case of radiology. This specialized technique necessitates use of tools and markers that are highly compatible. Many devices and markers, including fiducial markers, which are commercially sold, undergo MRI evaluations with respect to various safety issues and artifacts.

Presence of immoderate ferromagnetism that confine or obscure the target area is one of the primary reasons making commercially available devices unsuitable for MR-guided biopsy sessions. To overcome this, manufacturers are focusing on using materials with low magnetic susceptibility during manufacturing, in order to enhance compatibility of their products with MR-guided procedures. MRI compatible fiducial markers are usually longer than the standard variant, which minimizes the use of multiple needle sticks involved. Moreover, innovative designs used in case of MRI non-magnetic fiducial markers curb bending issues whilst injection processes, unlike the other linear tissue markers.

Competitive Landscape – Notable Strategies and Developments

  • Eckert & Ziegler BEBIG entered into an agreement with RaySearch Laboratories in the year 2018. With this agreement, Eckert & Ziegler BEBIG aims to leverage new opportunities in the field of brachytherapy- the treatment of prostate cancer through insertion of implants.
  • Boston Scientific agreed on a $4.24 billion deal to acquire BTG plc, a company offering products for minimally-invasive procedures for treating cancer and vascular diseases, in the year 2018. This acquisition was aimed at bolstering the organization’s capabilities in interventional medicine.
  • IBA Dosimetry announced ProMed Technologies as the company’s new and exclusive distributor partner for Canada region in the year 2017. This strategic move was aimed at ensuring the organization’s quality sales across prominent regions.
  • IZI Medical Products, Inc. announced the completion of its acquisition of the vertebral augmentation systems of Benvenue Medical, Inc. This acquisition was aimed at reinvigorating the company’s potential apropos of offerings for treatment of spinal fractures.

The report on fiducial markers also features various other companies operating in the global market space. The other players profiled in the report include Innovative Oncology Solutions, Best Medical International, Inc., Carbon Medical Technologies, CIVCO, alphaXRT, Nanovi Radiotherapy A/S, and Stellar Medical.

Reset Password